Day: June 2, 2020

Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline

Sanofi : Présentation de la stratégie en oncologie et de l’actualité des projets en cours et émergents du portefeuille de R&D  

PRESS RELEASE                                                                                              Paris, June 2, 20202019-2020 First-Half ResultsThe initial benefits of our reorganization blacked out by the impact of the health crisis and depreciation of goodwill·Analysis of 2019-2020 first-half resultsThe decline in current operating income over the first-half of 2019-2020 was due primarily to the drop in revenue from Agricultural and Industrial Spraying due to the global health crisis. The reorganization initiated in 2019 produced visible results for the Sugar Beet Harvesting business. With respect to Agricultural Spraying, we expect an improvement by the end of the financial year.The very uncertain macro-economic context, notably as a result of the health crisis, has led us to increase the overall level of general risk taken...

COMMUNIQUE DE PRESSE                                                                          Paris, le 2 juin 2020Résultat Semestriel 2019-2020Les premiers bénéfices de la réorganisation masqués par l’impact de la crise sanitaire et la dépréciation de goodwill·Analyse du résultat semestriel 2019-2020Sur le premier semestre 2019-2020, la baisse du résultat opérationnel courant provient principalement de la baisse du chiffre d’affaires des activités de Pulvérisation Agricole et de Pulvérisation Industrielle dans le contexte de la crise sanitaire mondiale.  Le plan de réorganisation lancé en 2019 produit des résultats visibles sur l’activité Arrachage de Betteraves. Au niveau de l’activité Pulvérisation Agricole, nous attendons des améliorations pour la fin de l’exercice fiscal.Le contexte macro-économique très incertain, notamment lié...

Pratteln, Switzerland, June 2, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. has completed a long-term, open-label extension study of 24 months duration with vamorolone in patients with Duchenne muscular dystrophy (DMD). Including 6 months treatment in the preceding study, ReveraGen has now obtained safety and efficacy data with vamorolone over a period of 2.5 years in 41 boys with DMD.Eligible for enrolment into the now completed 24-month long-term, open-label extension study (VBP15-LTE, clinicaltrials.gov ID: NCT03038399) were boys who had previously completed the 6-month dose escalation study VBP15-003 (clinicaltrials.gov ID: NCT02760277). Data from this VBP15-003 study in comparison to natural history study data demonstrated dose-dependent improvement in timed function tests. Vamorolone...

Pratteln, Schweiz, 2. Juni 2020 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Partnerunternehmen ReveraGen Biopharma Inc. eine langfristige, offene Anschlussstudie von 24 Monaten Dauer mit Vamorolone bei Patienten mit Duchenne-Muskeldystrophie (DMD) abgeschlossen hat. Zusammen mit einer 6-monatigen Behandlungsdauer in einer vorangehenden Studie hat ReveraGen nun Daten zur Verträglichkeit und Wirksamkeit mit Vamorolone über einen Zeitraum von 2.5 Jahren bei 41 Knaben mit DMD erhoben.Teilnahmeberechtigt für die jetzt abgeschlossene 24-monatige langfristige, offene Anschlussstudie (VBP15-LTE, clinicaltrials.gov ID: NCT03038399) waren Knaben, die zuvor die 6-monatige Studie VBP15-003 mit ansteigender Dosierung (clinicaltrials.gov ID: NCT02760277) abgeschlossen hatten. Im Vergleich zu Daten einer Studie zum natürlichen Krankheitsverlauf...

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinomaTecentriq combination improved overall survival and progression-free survival compared to the previous standard of careApplication approved under FDA’s Project Orbis initiative and Real-Time Oncology Review pilot programmeBasel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on...

Munich/Antwerp, 2 June 2020, 7:00 am CESTVGP NV (“VGP”), the Antwerp-based European provider of high-quality logistics and semi-industrial real estate, and Allianz have expanded their strategic partnership by entering an agreement in respect of a new 50:50 joint venture for the development of VGP Park München.The managerial and governance setup of the new partnership is similar to the existing two joint ventures between the two partners. VGP will serve the new joint venture as its sole asset, property and development manager.  Allianz Real Estate will manage the joint venture on behalf of Allianz group companies. Contrary to the two existing joint ventures which concentrate on the acquisition of income-generating assets developed by VGP, this new joint venture will initially be focussed on the development of VGP Park München.Once fully...

München/Antwerpen, 2 juni 2020, 7:00 CETVGP NV (“VGP”), de in Antwerpen gevestigde pan-Europese ontwikkelaar, beheerder en eigenaar van logistiek en semi-industrieel vastgoed, en Allianz hebben hun strategisch partnerschap uitgebreid door een overeenkomst te sluiten met betrekking tot een nieuwe 50:50 joint venture voor de ontwikkeling van VGP Park München.De management- en bestuursstructuur van het nieuwe partnerschap is vergelijkbaar met de twee bestaande joint ventures tussen de twee partners. VGP zal de nieuwe joint venture als enige asset-, vastgoed- en ontwikkelingsmanager dienen. Allianz Real Estate zal de joint venture namens de bedrijven van de Allianz-groep beheren. In tegenstelling tot de twee bestaande joint ventures die zich concentreren op de verwerving van door VGP reeds ontwikkelde prime assets, zal deze nieuwe...